Stratipath Medical
- Company typePrivate
- Founded2019
- HeadquartersStockholm, Sweden
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
Stratipath Medical firmographics
Firmographics- Name
- Stratipath Medical
- Legal name
- Stratipath AB
- Website
- https://stratipath.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Stratipath Medical industry classification
Industry- Product category
- AI-based cancer diagnostics software
- NAICS
- Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk) (HLAAAMAF)
- akta.pro secondary industry
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
Keywords
Where Stratipath Medical is headquartered
LocationHeadquarters
- HQ city
- Stockholm
- HQ country
- Sweden
- HQ region
- Europe
Offices1 record
Markets served
Stratipath Medical business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Software as a Service (SaaS) subscription: Access to Stratipath Breast provided as a Software as a Service solution, available via subscription or pay-as-you-use model. Revenue generated through recurring subscription fees from pathology labs and hospitals.
- Pay-per-use: Alternative consumption-based model allowing healthcare providers to pay per analysis rather than fixed subscription, providing flexibility for varying usage volumes.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Pay-as-you-go | SaaS subscription model for pathology labs and hospitals |
| Usage-based | Pay-as-you-go | Per-analysis pricing for healthcare providers |
Go-to-market motion3 records
Distribution channels6 records
Marketing channels9 records
Stratipath Medical product offering
Product offeringCore offering
Stratipath develops and sells Stratipath Breast, a CE-IVD marked AI software solution that performs prognostic risk profiling of invasive early-stage breast cancer by analyzing routine H&E-stained histopathology whole-slide images with deep learning. Delivered as a SaaS subscription or pay-per-use, the product is integrated with leading digital pathology platforms (Roche navify, Sectra, Proscia, Paige, PathAI, Visiopharm, Diagnexia) and used by pathology labs, hospitals, and oncology clinics in the EU, UK, and select international markets.
Product overview
Stratipath offers an AI-based precision diagnostics platform focused on cancer treatment decisions. The company's primary offering is Stratipath Breast, a first-in-class CE-IVD marked AI solution for prognostic risk profiling of breast cancer. The platform leverages deep learning technologies to analyze routine H&E-stained histopathology images, providing rapid risk stratification (results within one hour) as an alternative to traditional gene expression tests. The solution is delivered as a Software as a Service (SaaS) model, integrated with leading digital pathology platforms including Roche navify, Sectra, Proscia, Paige, Visiopharm, and Diagnexia.
Differentiator
Problem solved
Functional benefit
Brands
- Stratipath Breast: First-in-class CE-IVD marked AI solution for prognostic risk profiling of invasive early-stage breast cancer using H&E-stained histopathology images.
Products and services
- Stratipath Breast CE-IVD and IVDR CE-marked AI software for prognostic risk profiling of invasive early-stage breast cancer. Analyzes routine H&E-stained histopathology whole-slide images to classify tumors into low- and high-risk categories and to further resolve intermediate-risk (NHG2) cases, supporting oncologists and pathologists in treatment decision-making. Delivered as a SaaS subscription or pay-per-use via Stratipath's customer web portal and integrated with Roche navify, Sectra, Proscia, Paige, PathAI, and Visiopharm digital pathology platforms.
Quantifiable outcome
- Hazard Ratio (HR) of 2.76 between high- and low-risk groups in ER+/HER2- patients in multivariable analysis
- +4 more outcomes
Companies that use Stratipath Medical
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
Stratipath Medical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration6 records
AI capability4 records
Feature5 records
Stratipath Medical partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core.
- PathAIcoreStrategic collaboration to make Stratipath Breast available within PathAI's AISight Dx Image Management System. Expands access to AI-based precision diagnostics through PathAI's global digital pathology network.
- VisiopharmcoreStrategic collaboration to advance implementation of AI-powered breast cancer diagnostics. Combines Visiopharm's digital pathology solutions with Stratipath Breast for enhanced diagnostic workflows.
- DiagnexiacoreStrategic partnership to bring Stratipath Breast to pathology laboratories, hospitals, and healthcare providers across the UK and Europe. Diagnexia is a global leader in AI-powered digital pathology with state-of-the-art facilities in Oxford and Exeter. Collaboration integrates Stratipath's technology with Diagnexia's digital pathology network.
- UnilabscoreUnilabs implementing Stratipath Breast for enhanced breast cancer diagnostics at Capio S:t Göran's Hospital. Three-way collaboration marks significant step towards expanding access to advanced breast cancer diagnostics. Capio St Göran's treats more than 600 breast cancer patients annually.
- RochecoreNon-exclusive collaboration where Roche has distribution rights to integrated Stratipath solution. Integration with Roche's navify Digital Pathology enterprise software enables Roche customers to seamlessly perform prognostic risk profiling analyses. Represents significant step forward in breast cancer diagnostics by leveraging Roche's global distribution network.
- PaigecoreStratipath is now part of Paige AppLab, enabling integration with Paige's digital pathology platform and expanding market reach.
- ProsciacorePartnership to help oncologists and pathologists determine most suitable treatment path for more breast cancer patients. Stratipath is part of Proscia's new partner alliance 'Proscia Ready' focused on delivering integrated digital pathology solutions. Proscia is leading provider of digital and computational pathology solutions.
- SectracoreIntegration with Sectra's digital pathology solution enables Sectra users to use Stratipath Breast within existing digital pathology workflow. Application featured in Sectra Amplifier Marketplace and purchased directly from Stratipath. Sectra is international medical imaging IT company with over 2,000 installations globally.
- Swedish AI Precision Pathology (SwAIPP) ConsortiumcoreConsortium consisting of Stratipath, Karolinska Institutet, pathology clinics in Kalmar, Västmanland and Skåne regions, Microsoft, Roche Diagnostics, Philips, Bröstcancerförbundet, Prevas, and Helseplan. Funded by Vinnova with SEK 20 million grant to develop and implement AI-based precision diagnostics in cancer care. SwAIPP 2 continuation funded by Vinnova.
Scale indicators5 records
Recent moves7 records
Expansion highlights6 records
Stratipath Medical competitors and assessment
Company assessmentOthers
- Exact Sciences: Exact Sciences owns Oncotype DX, an established gene expression test for breast cancer recurrence risk that Stratipath Breast is positioned to substitute. While based on a different technology (molecular rather than AI image analysis), it competes for the same adjuvant chemotherapy decision support budget.
Direct peers
- Proscia: Proscia offers a digital and computational pathology platform with AI applications including its own Proscia Ready partner ecosystem (which includes Stratipath). It is a direct competitor and partner in digital pathology AI.
- Visiopharm: Visiopharm provides AI image analysis and workflow software for pathology, including cancer diagnostics. It is both a partner of Stratipath and a direct competitor in AI-driven pathology decision support.
- Paige.AI: Paige builds AI applications for cancer pathology, including FDA-cleared products for prostate and breast cancer detection. Paige is a direct competitor in AI-driven cancer diagnostics and is also a distribution partner of Stratipath through Paige AppLab.
- Sectra: Sectra is an international medical imaging IT and digital pathology company with over 2,000 installations globally, hosting Stratipath Breast in its Amplifier Marketplace. It is a direct comparable in enterprise digital pathology and a distribution partner.
- PathAI: PathAI develops AI-powered pathology products for cancer diagnosis and biomarker discovery, including the AISight Dx Image Management System with which Stratipath is already integrated. PathAI is both a partner and the most direct comparable in AI pathology for oncology.
- Ibex Medical Analytics: Ibex develops AI-powered diagnostic products for cancer pathology, with deployments in pathology labs worldwide. It is a direct peer in AI-based cancer diagnostics and shares the same target customer (pathology labs) and go-to-market motion.
Broad incumbents
- Tempus Labs: Tempus is a broad AI-driven precision medicine company spanning oncology diagnostics, multi-omics, and clinical trial support. While not focused specifically on pathology image AI, it competes for the same oncology customer budget and adjacent AI diagnostic slots.
- Roche (Digital Pathology): Roche operates navify Digital Pathology, the enterprise platform that distributes Stratipath Breast. As a global diagnostics incumbent with its own AI ambitions, Roche is both the largest channel partner and the largest latent competitive threat.
Emerging players
- Owkin: Owkin applies AI to oncology and other therapeutic areas, with both biopharma R&D and diagnostic products. It is an emerging player in AI-driven precision oncology with partial overlap in AI cancer diagnostics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Stratipath Medical social profiles
Digital presenceStratipath Medical compliance and trust
Trust signalCompliance3 records
Stratipath Medical financial estimates
Financial estimateRevenue estimate
Valuation estimate
Stratipath Medical leadership team
Management profileNumber of profiles
Profiles6 records
Stratipath Medical funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Stratipath Medical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Stratipath Medical
What does Stratipath Medical do?
Stratipath develops and sells Stratipath Breast, a CE-IVD marked AI software solution that performs prognostic risk profiling of invasive early-stage breast cancer by analyzing routine H&E-stained histopathology whole-slide images with deep learning. Delivered as a SaaS subscription or pay-per-use, the product is integrated with leading digital pathology platforms (Roche navify, Sectra, Proscia, Paige, PathAI, Visiopharm, Diagnexia) and used by pathology labs, hospitals, and oncology clinics in the EU, UK, and select international markets.
Is Stratipath Medical a public or private company?
Stratipath Medical is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Stratipath Medical founded?
Stratipath Medical was founded in 2019. It employs 11 to 50 people.
Where is Stratipath Medical based?
Stratipath Medical is headquartered in Stockholm, Sweden, in the Europe region.
How does Stratipath Medical make money?
Two revenue lines are on record. Software as a Service (SaaS) subscription is the primary driver. The others are pay-per-use.
Who are Stratipath Medical's main competitors?
Exact Sciences is listed as an others. Direct peers are Proscia, Visiopharm, Paige.AI, Sectra, PathAI and Ibex Medical Analytics. Broad incumbents are Tempus Labs and Roche (Digital Pathology). Owkin is listed as an emerging player.
Does Stratipath Medical have an API?
No public API is recorded for Stratipath Medical.
What industry is Stratipath Medical in?
Stratipath Medical's product category is AI-based cancer diagnostics software. Its primary akta.pro industry code is HLAAAMAF, Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk), with a secondary code of HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy). Its NAICS code is 621511 and its SIC code is 8071.